The firm's financial position is characterized by a deteriorating equity base with an accumulated deficit of $15.9 million as of 2026Q1, despite maintaining a current ratio of 10.31.
| Total Current Assets | 4.44M | 5.39M | 4.17M | 101K | 437K | 73K | 14.31K |
| Cash & Short-Term Investments | 3.67M | 4.49M | 1.27M | 93K | 437K | 73K | 14.31K |
| Cash Only | 3.67M | 4.49M | 1.27M | 93K | 437K | 73K | 14.31K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 768K | 896K | 38K | 8K | 0 | 0 | 0 |
| Total Non-Current Assets | 1.3M | 1.15M | 2.05M | 864K | 599K | 702K | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 22K | 62K | 222K | 382K | 542K | 702K | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.28M | 1.09M | 1.38M | 482K | 57K | 0 | 0 |
| Total Assets | 5.74M | 6.54M | 6.22M | 965K | 1.04M | 775K | 14.31K |
| Asset Turnover | 0.00x | - | - | - | - | - | - |
| Asset Growth % | 586.64% | 5.21% | 544.15% | -6.85% | 33.68% | 5316.55% | - |
| Total Current Liabilities | 431K | 199K | 992K | 2.4M | 1.63M | 1.94M | 357.15K |
| Accounts Payable | 0 | 0 | 0 | 2.4M | 1.63M | 1.55M | 307.15K |
| Days Payables Outstanding | -771.06 | - | - | 5.48K | 3.72K | 5.77K | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 4K | 380K | 50K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 431K | 199K | 992K | 0 | 0 | 14K | 0 |
| Current Ratio | 10.31x | 27.07x | 4.20x | 0.04x | 0.27x | 0.04x | 0.04x |
| Quick Ratio | 10.31x | 27.07x | 4.20x | 0.04x | 0.27x | 0.04x | 0.04x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 448K | 638K | 582K | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 638K | 582K | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 448K | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 431K | 199K | 1.44M | 3.04M | 2.21M | 1.94M | 357.15K |
| Total Debt | 0 | 0 | 0 | 638K | 586K | 380K | 50K |
| Net Debt | -3.67M | -4.49M | -1.27M | 545K | 149K | 307K | 35.69K |
| Debt / Equity | 0.00x | - | - | - | - | - | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.62x | - | - | - | - | - | - |
| Interest Coverage | - | - | -2.03x | -17.49x | -1.19x | -9.62x | -193.30x |
| Total Equity | 5.31M | 6.34M | 4.78M | -2.08M | -1.18M | -1.17M | -342.84K |
| Equity Growth % | 463.24% | 32.77% | 329.84% | -76.25% | -1.03% | -240.39% | - |
| Book Value per Share | 0.25 | 0.34 | 0.42 | -0.20 | -0.12 | -0.09 | -0.03 |
| Total Shareholders' Equity | 5.31M | 6.34M | 4.78M | -2.08M | -1.18M | -1.17M | -342.84K |
| Common Stock | 21K | 21K | 14K | 11K | 10K | 10K | 192.39K |
| Retained Earnings | -15.92M | -14.26M | -8.81M | -6.21M | -4.4M | -3.35M | -1.2M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and dilution
According to recent financial disclosures, Kairos Pharma's total assets have declined from $8.1 million in 2025Q3 to $5.7 million in 2026Q1, signaling a rapid depletion of resources as the company struggles to sustain its clinical development pipeline without a recurring revenue base.
The downward trend in total assets reflects the ongoing consumption of cash to fund R&D activities, which appears to be outpacing the company's ability to replenish its balance sheet. This trajectory suggests that the firm is approaching a critical juncture where the current asset base may no longer support the necessary scale of its clinical trials.
Based on reported figures, the company's cash position has fluctuated significantly, dropping to $3.7 million in 2026Q1, which warrants close monitoring given the high burn rate inherent in the firm's current Phase 2 oncology trial programs and limited access to non-dilutive capital.
While the current ratio of 10.31 appears superficially healthy, it is largely a function of the company's minimal current liabilities rather than an abundance of liquid assets. Investors should interpret this liquidity profile as highly fragile, as any unexpected delay in clinical milestones could rapidly exhaust the remaining cash runway.
As reported in financial statements, the company's retained earnings have deteriorated to a deficit of $15.9 million as of 2026Q1, illustrating the persistent impact of historical operating losses on the firm's total equity position and overall financial health.
The consistent expansion of the accumulated deficit highlights the structural challenge of funding long-term R&D through equity without achieving commercial milestones. This trend suggests that future financing rounds will likely be highly dilutive to existing shareholders, as the company lacks the retained earnings buffer to absorb further operational setbacks.
Based on the provided balance sheet data, the company carries $22,000 in goodwill, a figure that appears increasingly disconnected from the firm's enterprise value and may indicate potential impairment risks if the clinical efficacy of the ENV101 program fails to meet market expectations.
The presence of goodwill on a pre-revenue balance sheet warrants further investigation, as it may represent legacy acquisition costs that hold little relevance to the current clinical-stage business model. Analysts should consider this a potential distortion that masks the true, asset-light nature of the firm's core R&D operations.
Quick answers to the most common questions about buying KAPA stock.
As of 2025, Kairos Pharma, Ltd. (KAPA) had total assets of $6.5M including $5.4M in current assets.
Kairos Pharma, Ltd. (KAPA) carries total debt of $0.0M, offset by $4.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Kairos Pharma, Ltd. (KAPA) has total shareholders' equity (book value) of $6.3M ($0.34 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Kairos Pharma, Ltd. (KAPA) reported a current ratio of 27.07x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.